Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP8 | P40818 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362305 | 0.81 | SRC (0.39) | HPGDSUSP8CYP11B1CYP11B2NQO1 | |
| SCHEMBL1846308 | 0.81 | HPGDS (0.39) | HPGDSMAPK1USP8CYP11B1CYP11B2 | |
| SCHEMBL28757822 | 0.80 | CYP11B1 (0.40) | CYP11B1CYP11B2PIK3CDLMNA | |
| SCHEMBL361785 | 0.80 | PIK3CD (0.32) | CYP11B1CYP11B2PIK3CD | |
| SCHEMBL1006358 | 0.79 | MAPT (0.46) | HPGDSPOLBUSP8CYP11B1CYP11B2 | |
| SCHEMBL18036083 | 0.79 | CYP11B1 (0.44) | HPGDSTSHRUSP8CYP11B1CYP11B2 | |
| SCHEMBL26697698 | 0.79 | PIK3CD (0.51) | HPGDSUSP8RECQLCYP11B1CYP11B2 | |
| SCHEMBL29935957 | 0.79 | PIK3CD (0.51) | HPGDSUSP8RECQLCYP11B1CYP11B2 | |
| SCHEMBL362114 | 0.79 | ADORA2A (0.37) | TSHRRECQLCYP11B1CYP11B2PIK3CD | |
| SCHEMBL16461718 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10875860-B2 | Azaindenoisoquinoline compounds and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200095243-A1 | AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-03-26 | — | — | US | disclosed |
| EP-3558993-A1 | AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF | Purdue Research Foundation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20140187547-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140018360-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION | 2014-01-16 | — | — | US | disclosed |
| US-20140018360-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION | 2014-01-16 | — | — | US | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2663559-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20070037286-A1 | Thyroxine-containing compound analysis methods | APPLIED BIOSYSTEMS, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | HPGDS 1954/4885MAPK1 2158/4885TSHR 2929/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | HPGDS 3085/4885MAPK1 2298/4885TSHR 3283/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | HPGDS 1215/4885MAPK1 2622/4885TSHR 1191/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | HPGDS 1023/4885MAPK1 3368/4885TSHR 1832/4885 |
| US-20140187547-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | TOP2A, TOP1, TOP2B | HPGDS 1411/4885MAPK1 3588/4885TSHR 4360/4885 |
| US-10875860-B2 | Azaindenoisoquinoline compounds and uses thereof | TDP1, TDP2, TOP1 | HPGDS 1959/4885MAPK1 2988/4885TSHR 4395/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | HPGDS 1215/4885MAPK1 2622/4885TSHR 1191/4885 |
| US-20140018360-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | TOP2A, TOP1, TOP2B | HPGDS 1411/4885MAPK1 3588/4885TSHR 4360/4885 |
| US-20200095243-A1 | AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF | TDP1, TDP2, TOP1 | HPGDS 1959/4885MAPK1 2988/4885TSHR 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.